Specialty Pharmacy

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.

New technique allows physicians to see if a tumor is susceptible or resistant to treatment much earlier than conventional methods.

Findings on x-linked reticulate pigmentary disorder (XLPDR) could lead to new targeted therapies.

Marc O'Connor, chief operating officer of Curant Health, discusses efficiency in specialty pharmacy relationships.

Atezolizumab treats locally advanced or metastatic NSCLC expressing the PD-L1 protein.

Top news of the day across the health care landscape.

There are currently no treatments deemed effective in slowing down the progression of FTD.

A large proportion of patients with multiple sclerosis experience taste deficits.

A better understanding of the dynamics of the immune system's response to HIV may lead to more effective IFNa-based therapies.

Low oxygen conditions encourage some cancer stem cells to multiply.

Rare effective antibodies taken from HIV patients serve as guides to reverse engineer optimal vaccine candidates.

New insulin caused blood sugar levels to fall in mouse models, creating hope for improved treatment of diabetes.

Recent advances and updates in oncology and cancer drug development.

Experimental drug could may lead to new treatments for AML, lung cancer, brain cancer, and melanoma.

Scoring can optimize limited resources to target specific patients.

Growing out-of-pockets costs associated with reduced utilization of specialty medications.

Top news of the day across the health care landscape.

Top articles of the week on Specialty Pharmacy Times.

Only 20% of lung cancer patients show a response to current immunotherapeutic antibodies.

Guide RNA shows promise eliminating HIV from the DNA of CD4 T cells.

Experimental drug bococizumab could fill the unmet needs of patients at risk for cardiovascular disease.

The combination drug Genvoya offers minor benefits in pretreated women and no benefit in pretreated men with HIV.

HO-1 offers an attractive therapeutic target for the treatment of inflammatory conditions.

Study finds that manufacturers need to develop a new approach to engaging oncologists.

Rebrand to focus on enhanced collaboration with member pharmacies, manufacturers, payers and other industry stakeholders to develop complete solutions for specialty pharmaceuticals.

PCSK9 inhibitor shows promise for statin-intolerant patients with muscle-related side effects.

Humira shows promise for pediatric Crohn’s disease patients who are intolerant to or had an inadequate response to conventional therapy.

People from poor or middle-income households with conditions such as diabetes or asthma face greater risk for serious mental illness.